MS Registries DMT Durability MSSS
Research type
Research Study
Full title
A study of contemporary disease modification and MS severity
IRAS ID
302659
Contact name
Neil Robertson
Contact email
Sponsor organisation
Cardiff University Research Integrity, Governance and Ethics Team
Clinicaltrials.gov Identifier
n/a, n/a
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
Multiple sclerosis (MS) is a lifelong neurological condition, and one of the leading causes of disability in young people. Whilst there is no cure for MS, clinical trials have shown that disease-modifying treatments (DMTs) offer significant reductions in disability and improve outcomes for people living with this condition. DMT persistence (time on treatment) is a key factor in overall treatment success, but long-term real-world data on DMT persistence in MS is lacking.
In addition, population data on the MS disease trajectory has previously been modelled as an MS severity score (MSSS), describing rates of disease progression in a representative cohort. However, the MSSS was modelled using outcome data from a pre-DMT era. It would therefore be valuable to model disability trajectory in a contemporary real-world disease-modified UK population using this method.
This population-based cohort study aims to explore patterns of DMT use and model the distribution of disability progression within multi-centre real-world datasets. Analysing the length of time people with MS spend on individual DMTs, and the reasons they stop or switch particular DMTs is vital to understand which DMTs may have the highest, long-term effectiveness in the population. This study has the potential to inform clinical decision-making to achieve the best possible outcomes for people living with MS.
REC name
N/A
REC reference
N/A